Preemptive Pharmacogenomic Testing Versus Reactive Genotyping Improves Effectiveness and Lowers Costs

No comments
<br />
<b>Warning</b>:  Undefined variable $post_id in <b>/home/c7ohf3687z7b/public_html/wp-content/themes/igx/single.php</b> on line <b>110</b><br />

Physicians often test patients when a reaction to medicine occurs, but what if there is testing to see how well a patient will metabolize medicine before they take it? The field of pharmacogenomics can often determine this information before starting a new medicine and can save critical care time and the cost of medicines that don’t work well. A recent journal article examines the differences between preemptive pharmacogenomic testing versus reactive genotyping in a variety of patients.